2022 American Transplant Congress
The Effect of Adoption of Acuity Circles on Hepatocellular Carcinoma Transplantation Rates at a Single High Acuity Center
*Purpose: Transplantation for selected patient with HCC has been prioritized with a MELD exception since 2002. Further changes have decreased the maximum exception for HCC.…2022 American Transplant Congress
Center-Level Variability in DDLT Rate Before and After the Implementation of MMaT/250 Score
Johns Hopkins Medical Institutions, Baltimore, MD
*Purpose: In 02/2020, OPTN replaced DSA/regional boundaries with acuity circles and substituted exception scores for individual patients to median-MELD-at-transplant within 250 nautical miles of a…2022 American Transplant Congress
Cell-free Amniotic Fluid Reduces Liver Inflammation And Fibrosis
*Purpose: Effective interventions for hepatic inflammation and fibrosis remain a dire unmet need in transplant medicine. Cell-free amniotic fluid (AF) represents a potential alternative to…2022 American Transplant Congress
Locoregional Therapy and Long-Term Post-Transplant Outcomes for HCC Liver Transplant Recipients
Johns Hopkins Medical Institutions, Baltimore, MD
*Purpose: In last decade, locoregional therapy (LRT) have been widely used to downstage HCC patients in order to qualify for liver transplantation. Large-scale direct comparisons…2022 American Transplant Congress
Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence
1Rutgers New Jersey Medical School, Newark, NJ, 2Houston Methodist Hospital, Houston, TX
*Purpose: Despite stringent selection criteria for liver transplant (LT) in patients with liver-limited malignancy, post-transplant cancer recurrence remains problematic. We have previously identified a pre-LT…2022 American Transplant Congress
The Impact of Yttium-90 Radioembolization on T Cell Phenotypes in Bridged to Transplant Hepatocellular Carcinoma Patients
Ochsner Health System, New Orleans, LA
*Purpose: Response to locoregional therapy (LRT) in hepatocellular carcinoma (HCC) impacts both progression-free survival (PFS) and bridge to transplant success. Yttrium-90 (Y90) is an effective…2022 American Transplant Congress
Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…2022 American Transplant Congress
Impact of MMaT Policy on Transplant for Hepatocellular Carcinoma at a Single Center
*Purpose: Hepatocellular carcinoma (HCC) is the most common primary malignant hepatic tumor. Currently, liver transplantation may be the optimal treatment for HCC. Patient selection criteria…2022 American Transplant Congress
Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for T2 Hepatocellular Carcinoma and May Allow for Decreased Mortality
*Purpose: Prior studies have suggested that induction therapy leads to worse outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study evaluated the impact…2022 American Transplant Congress
A Intention-to-Treat Analysis of 881 Consecutively Waitlisted Patients to Develop a Survival Benefit Model for Hepatocellular Carcinoma Liver Transplant Candidates
*Purpose: The current liver transplantation (LT) selection paradigm for hepatocellular carcinoma (HCC) patients ignores the variable risks of waitlist dropout and post-LT recurrence/death, with the…
- 1
- 2
- 3
- …
- 23
- Next Page »